Following some clean sweeps in PhIII, AbbVie gets an FDA OK on its top-10 blockbuster prospect Orilissa
One of the year’s top prospective blockbuster approvals just came through.
AbbVie $ABBV says that they just nabbed an FDA OK for elagolix — the first new oral drug approved for endometriosis pain in more than a decade.
The drug will be rolled out into the marketplace under the name Orilissa, which analysts tap as a likely $1.2 billion-plus drug, fitting well into EPVantage’s list of top 10 experimental drugs for 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.